Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis.
Future Oncol
; 16(10): 585-596, 2020 Apr.
Article
em En
| MEDLINE
| ID: mdl-32166978
ABSTRACT
Aim:
Poly(ADP-ribose) polymerase inhibitors (PARPIs) improved progression-free survival among patients with recurrent ovarian cancer. This meta-analysis examined the effectiveness of PARPIs as maintenance strategy for newly diagnosed patients with advanced high-grade ovarian cancer with or without mutations. Materials &methods:
Using defined selection criteria, a literature search identified four eligible randomized clinical trials involving 2386 patients.Results:
Compared with placebo maintenance, PARPIs achieved a 46% reduction in the risk of progression or death as compared with placebo (hazard ratio 0.54; 95% CI 0.39-0.73; p < 0.0001). That benefit was shown in all clinical subgroups among those with BRCA mutation, with negative/unknown BRCA mutation, and in those with homologous recombination deficient tumors. Data about the effect on overall survival are still premature.Conclusion:
In patients with newly diagnosed advanced ovarian cancer, PARPIs maintenance after standard therapy achieved a significant improvement in progression-free survival as compared with placebo, overall and in all subgroups.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Inibidores de Poli(ADP-Ribose) Polimerases
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article